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IgG4 inhibits peanut-induced basophil and mast cell
activation in peanut-tolerant children sensitized
to peanut major allergens
Alexandra F. Santos, MD, MSc,a,b,c,d Louisa K. James, PhD,b,e Henry T. Bahnson, MPH,f Mohammed H. Shamji, PhD,b,g
Natalia C. Couto-Francisco, MSc,a,b Sabita Islam, PhD,h Sally Houghton, MSc,i Andrew T. Clark, FRCPCH,j
Alick Stephens, PhD,a,b Victor Turcanu, PhD,a,b Stephen R. Durham, MD, FRCP,b,g Hannah J. Gould, PhD,b,e and
Gideon Lack, MD, FRCPCHa,b London and Cambridge, United Kingdom, Coimbra and Lisbon, Portugal, and Chapel Hill, NC
Background: Most children with detectable peanut-specific IgE
(P-sIgE) are not allergic to peanut.We addressed 2 non–mutually
exclusive hypotheses for the discrepancy between allergy and
sensitization: (1) differences in P-sIgE levels between children
with peanut allergy (PA) and peanut-sensitized but tolerant (PS)
children and (2) the presence of an IgE inhibitor, such as
peanut-specific IgG4 (P-sIgG4), in PS patients.
Methods: Two hundred twenty-eight children (108 patients with
PA, 77 PS patients, and 43 nonsensitized nonallergic subjects)
were studied. Levels of specific IgE and IgG4 to peanut and its
components were determined. IgE-stripped basophils or a mast
cell line were used in passive sensitization activation and
inhibition assays. Plasma of PS subjects and patients submitted
to peanut oral immunotherapy (POIT) were depleted of IgG4
and retested in inhibition assays.
Results: Basophils and mast cells sensitized with plasma from
patients with PA but not PS patients showed dose-dependent
activation in response to peanut. Levels of sIgE to peanut and its
components could only partially explain differences in clinical
reactivity between patients with PA and PS patients. P-sIgG4
levels (P 5 .023) and P-sIgG4/P-sIgE (P < .001), Ara h 1–sIgG4/
Ara h 1–sIgE (P5 .050), Ara h 2–sIgG4/Ara h 2–sIgE (P5 .004),
and Ara h 3–sIgG4/Ara h 3–sIgE (P 5 .016) ratios were greater
in PS children compared with those in children with PA.
Peanut-induced activation was inhibited in the presence of
plasma from PS children with detectable P-sIgG4 levels and
POIT but not from nonsensitized nonallergic children.
Depletion of IgG4 from plasma of children with PS (and POIT)
sensitized to Ara h 1 to Ara h 3 partially restored peanut-
induced mast cell activation (P 5 .007).
Conclusions: Differences in sIgE levels and allergen specificity
could not justify the clinical phenotype in all children with PA
and PS children. Blocking IgG4 antibodies provide an additional
explanation for the absence of clinical reactivity in PS patients
sensitized to major peanut allergens. (J Allergy Clin Immunol
2015;135:1249-56.)
Key words: Ara h 2, basophil, basophil activation test, blocking
antibodies, IgE inhibition, IgG4, mast cells, peanut, peanut allergy,
tolerance
Sensitization is the first stage in the development of
IgE-mediated food allergy. Clinically, it is demonstrated by a
positive skin prick test (SPT) response or detectable allergen-
specific IgE antibodies in serum. However, allergic sensitization
does not always lead to clinical allergy. In fact, the majority of
subjects with detectable food-specific IgE do not have any allergic
symptoms when consuming the food.1,2 In other words, allergen-
specific IgE is necessary but not sufficient for the development of
immediate-type food allergy.
The discrepancy between allergic sensitization and clinical
food allergy creates diagnostic difficulties and a fundamental gap
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Abbreviations used
HSA: Human serum albumin
NA: Non–peanut-sensitized nonallergic
PA: Peanut allergy
POIT: Peanut oral immunotherapy
P-sIgE: Peanut-specific IgE
P-sIgG4: Peanut-specific IgG4
PS: Peanut-sensitized but tolerant
SPT: Skin prick test
in our knowledge about the mechanisms of food allergy and
tolerance. We have used peanut allergy (PA) as a model of
IgE-mediated food allergy. Specific IgE to Ara h 2 is particularly
discriminative in identifying patients with PA.1,3 However,
examples can be found of peanut-tolerant patients who have
high levels of Ara h 2–specific IgE and conversely of patients
with PA who have negative test results to Ara h 2 and the other
major peanut allergens.4 Basophils and mast cells are the effector
cells of acute allergic reactions to foods, including anaphylaxis. In
a previous study we showed that a whole-blood basophil
activation test has high accuracy in the diagnosis of PA and
correlates very closely with the clinical phenotype of
IgE-sensitized patients (ie, allergic vs tolerant patients) at a level
better than measurement of specific IgE levels to peanut, Ara h 2,
or any of the other peanut components.5 Similar in vitro systems
using passive sensitization of basophils or mast cells with
patients’ plasma can be used to test the ability of allergen-
specific IgE antibodies present in the plasma to elicit effector
cell activation and degranulation in response to the allergen.
In this study we addressed 2 non–mutually exclusive
hypotheses to explain the discrepancy between allergic
sensitization and clinical allergy. The first hypothesis was that
the levels and specificity of IgE are different between allergic and
tolerant patients. The second hypothesis was that sensitized but
tolerant patients have an inhibitor that blocks the function of IgE.
Given that natural tolerance to food allergens is allergen specific
and long-lasting, the IgE inhibitor is likely to be a food-specific
antibody of an isotype other than IgE, such as IgG4. IgG4 levels
have been shown to increase in patients who naturally outgrow
IgE-mediated food allergy, such as cow’s milk allergy,6,7 and in
patients who are submitted to food oral immunotherapy8,9 and
immunotherapy to respiratory allergens.10-12 Whether IgG4 can
play an inhibitory role in the allergen-IgE interaction in sensitized
but otherwise tolerant patients is unknown. IgG4 is produced as
part of a TH2-type immune response induced mainly by the
tolerogenic cytokine IL-1013 and therefore was the main suspect
for being the IgE inhibitor in peanut-sensitized but tolerant (PS)
patients in this study.
METHODS
Study population
Children with PA, PS children, and non–peanut-sensitized nonallergic
(NA) children consecutively attending pediatric allergy clinics at a university
hospital or a private hospital in London were invited to participate in the study.
Patients were clinically evaluated, including oral food challenges to peanut,
if clinically indicated and as previously described.5 The patient’s allergic
status to peanut was determined by using oral food challenges, except for
(1) children with a convincing history of a systemic reaction or reactions to
peanut within 1 year of their visit and an SPT-induced wheal size of 8 mm
or greater,8 a peanut-specific IgE (P-sIgE) level of 15 KUA/L or greater,
8 or
both, who were considered to have PA, and (2) children who were able to
eat 4 g or more of peanut protein twice a week (as assessed by a validated
peanut consumption questionnaire14) without having allergic symptoms,
who were considered peanut tolerant. Peanut sensitization was defined as an
SPT-induced wheal size of 1 mm or greater, a P-sIgE level of 0.10 KUA/L
or greater, or both. Serum and plasma samples were collected simultaneously
for serology and for subsequent mast cell and basophil passive sensitization
experiments, respectively. The parents of all children signed an informed
consent form approved by the South East London Research Ethics
Committee 2.
Plasma samples collected before and after treatment from an independent
population of 19 patients with PAwho underwent peanut oral immunotherapy
(POIT) as part of the STOP I trial (registered at http://ClinicalTrials.gov with
the identification no. NCT01259804)15 were tested in parallel.
Serum specific IgE and IgG4 levels to peanut and
peanut components
Serum specific IgE and IgG4 to peanut extract and to the recombinant
peanut allergens rAra h 1, rAra h 2, rAra h 3, rAra h 8, and rAra h 9 were
measured with an immunoenzymatic assay (ImmunoCAP; Thermo Fisher,
Waltham, Mass). IgG4/IgE ratios were determined after conversion of
kilounits per liter (IgE) and milligrams per liter (IgG4) to nanograms per
milliliter.
IgG4 antibody depletion
IgG1 anti-IgG4 antibody (clone MH164-4; Sanquin, Amsterdam, The
Netherlands) was coupled to cyanogen bromide–activated Sepharose (GE
Healthcare, Hertfordshire, United Kingdom) during an overnight incubation
at 48C. The remaining reactive groups were blocked with 1 mol/L
ethanolamine, followed by 3 cycles of washes in alternating pH using
0.1 mol/L acetic acid/sodium acetate at pH 4.0 and 0.1 mol/L Tris-HCl at
pH 8.0. Mock-coupled Sepharose beads were processed in parallel with
anti-IgG4–coupled beads. Plasma samples were filtered and diluted 1:10 in
PBS-AT (0.3% BSA, 0.1% Tween 20, and 0.05% NaN3 in PBS). Diluted
plasma samples were incubated with anti-IgG4– or mock-coupled Sepharose
beads in a total volume of 500 mL overnight at room temperature with
continuous end-over-end rotation. IgG4- and mock-depleted samples were
collected by means of centrifugation. Total IgG4 plasma levels were measured
by means of ELISA in IgG4- and mock-depleted samples, as previously
described.16
Basophil and mast cell activation and inhibition
assays
For the basophil assays, PBMCs were isolated from citrate-dextrose–
anticoagulated blood of atopic non–peanut-sensitized adult volunteers
without peanut allergy by using density gradient separation with
Histopaque-1077 (Sigma-Aldrich, Poole, United Kingdom). For stripping of
receptor-bound IgE, PBMCs were resuspended in lactic acid (13.4 mmol/L
lactate, 140 mmol/L NaCl, and 5 mmol/L KCl [pH 3.9]) and incubated at 48C
for 5 minutes. Human serum albumin (HSA; 0.5%) in RPMI was added, and
the solutionwas neutralizedwith 12%Tris. After washingwith 0.5%HSA, the
cell pellet was resuspended in 0.5%HSA and incubated for 1 hour at 378Cwith
individual plasma from study participants. After washing, resensitized
PBMCs were stimulated with peanut extract (10 ng/mL; ALK-Abello,
Hørsholm, Denmark), anti-IgE (1 mg/mL, Sigma-Aldrich), formyl-
methionyl-leucyl-phenylalanine (1 mmol/L, Sigma-Aldrich), or 0.5% HSA
alone for 1 hour at 378C and stained with CD123–fluorescein isothiocyanate
(eBioscience, San Diego, Calif), HLA-DR–peridinin-chlorophyll-protein,
CD203c-phycoerythrin, and CD63-allophycocyanin (BioLegend, San Diego,
Calif), followed by flow cytometric analysis. Basophils were gated as side
scatter–low CD203c1 CD1231HLA-DR2 cells. The peanut extract used
contained all 3 major peanut allergens, Ara h 1, Ara h 2, and Ara h 3, as
previously reported.5 Basophil activation was expressed as the percentage
of CD631 basophils and as the stimulation index of CD203c.
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For the mast cell assays, LAD2 cells,17 which were kindly provided by Drs
Dean Metcalfe and Arnold Kirshenbaum (Laboratory of Allergic Diseases,
National Institute of Allergy and Infectious Diseases), were placed in culture
with rIL-4 for 5 days before overnight sensitization with patients’ plasma.
Sensitized cells were stimulated with peanut extract, anti-IgE, ionomycin,
or 0.04% BSA RPMI alone for 30 minutes at 378C and stained with
the viability dye eFluor 450 and CD107b–fluorescein isothiocyanate
(eBioscience), CD203c-phycoerythrin, CD107a-PerCPCy5.5, CD63-
allophycocyanin, and IgE-PECy7 (BioLegend) and analyzed by means of
flow cytometry. LAD2 cells were gated as CD203c1 viable cells. Mast cell
activation was expressed as the percentage of CD631 or CD107a1 cells.
For mast cell inhibition experiments, 20 mL of plasma from PS patients or
NA subjects or stimulation buffer was incubated with an equal volume of
stimulation buffer and 10 mL of allergen at 378C for 1 hour before LAD2 cells
previously sensitized with 100 mL of plasma from a patient with PA and
washed were added to the allergen-plasma mixture. For basophil inhibition
experiments, the 20mLof plasma froma patientwith PAwas incubatedwith 20
mLof plasma fromPS patients or NA subjects and allergen before addition of 1
million IgE-stripped PBMCs.The sameplasma frompatientswith PAwas used
in allmast cell inhibition experiments.Another plasma samplewith similar IgE
levels and patterns of sensitization to peanut allergens (ie, positive to Ara h 1,
Ara h 2, and Ara h 3) was used in all basophil inhibition experiments.
Flow cytometry was performed on a FACSCanto II with FACSDiva
software (BD Biosciences, San Jose, Calif), and data were analyzed with
FlowJo software (version 7.6.1; TreeStar, Ashland, Ore).
Statistical analyses
Qualitative variables were compared between children with PA and PS
children by using Fisher exact or x2 tests, and continuous variables were
compared by using the Mann-Whitney U or Kruskall-Wallis tests. For paired
analyses, the Wilcoxon signed-rank test was used. Statistical analyses were
performed with SPSS 20.0 (SPSS, Chicago, Ill) and JMP Pro 11.2.1 software
for Windows. Significance was determined by using a 2-sided a level of .05.
RESULTS
Study population
Two hundred twenty-eight children (108 children with PA and
110 peanut-tolerant children [77 PS and 43 NA children]) were
included in the study. Children with PA were slightly older
(median, 6 years) and more frequently had asthma (39.8%) and
allergic rhinitis (59.3%) than PS children (median, 4 years; 18.2%
with asthma and 31.2% with allergic rhinitis). The other
demographic and clinical features were similar between the 2
groups (Table I).
Passive sensitization basophil and mast cell assays
reproduced in vitro clinical reactivity to peanut
in vivo
In a previous study we showed that a whole-blood basophil
activation test reproduces very closely the clinical phenotype of
peanut-sensitized patients.5 Here we performed similar
experiments in which LAD2 cells or IgE-stripped primary
basophils from healthy donors were sensitized with plasma
from patients with PA, PS patients, or NA subjects before
stimulation with peanut extract. Mast cells sensitized with plasma
from patients with PA, but not from PS patients or NA subjects,
showed a dose-dependent activation in response to peanut
(Fig 1). The same findings were observed with primary human
basophils (see Fig E1 in this article’s Online Repository at
www.jacionline.org).
Levels of specific IgE to peanut and peanut
components only partially account for differences in
clinical reactivity to peanut between patients with
PA and PS patients
Patients with PA had higher levels of IgE to peanut (P < .001)
and Ara h 1 (P <.001), Ara h 2 (P <.001), and Ara h 8 (P5 .019)
than PS patients (Table I). However, there was a substantial
overlap between the 2 groups (see Fig E2 in this article’s
Online Repository at www.jacionline.org).
There was no obvious relationship between the profiles
of IgE sensitization to peanut allergens and clinical reactivity
TABLE I. Clinical features and serum specific IgE levels of the study population (n 5 228)
Patients with PA (n 5 108)
Peanut-tolerant subjects (n 5 110)
P value*PS patients (n 5 77) NA subjects (n 5 43)
Age (y) 6.0 (5.0-10.0) 4.0 (1.5-7.5) 5 (5.0-7.0) <.001
Male subjects, no. (%) 74 (68.5) 47 (61.0) 30 (69.8) .185
Other food allergy, no. (%) 94 (87.0) 67 (87.0) 9 (20.9) .582
Atopic eczema, no. (%) 71 (65.7) 46 (59.7) 18 (41.9) .248
Asthma, no. (%) 43 (39.8) 14 (18.2) 8 (18.6) .001
Allergic rhinitis, no. (%) 64 (59.3) 24 (31.2) 12 (27.9) <.001
Pollen allergy, no. (%) 51 (47.2) 25 (32.5) 9 (20.9) .075
Nonatopic, no. (%) 0 (0) 0 (0) 14 (32.6) —
SPT response to peanut (mm) 9 (7-12) 4 (1-8) 0 (0-0) <.001
Specific IgE (KUA/L)
Peanut 13.30 (2.26-98.70) 1.83 (0.48-5.20) 0.01 (0.01-0.02) <.001
Ara h 1 0.44 (0.04-31.13) 0.11 (0.01-0.34) 0.01 (0.01-0.01) <.001
Ara h 2 6.04 (0.90-54.55) 0.08 (0.03-0.25) 0.01 (0.01-0.04) <.001
Ara h 3 0.12 (0.02-2.41) 0.06 (0.02-0.34) 0.01 (0.01-0.01) .075
Ara h 8§ 0.08 (0.01-2.09) 0.01 (0.01-0.23) 0.01 (0.01-0.01) .019
Ara h 9k 0.01 (0.01-0.08) 0.02 (0.01-0.25) 0.01 (0.01-0.01) .169
For continuous variables, medians and interquartile ranges are indicated.
*P values refer to the comparison between patients with PA and PS patients using the Mann-Whitney U test. Values in boldface indicate statistical significance.
n 5 222.
n 5 221.
§n 5 220.
kn 5 219.
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(Table II and see Table E1 in this article’s Online Repository at
www.jacionline.org). The majority (69%) of patients with PA
were sensitized to more than 1 peanut allergen, whereas PS
patients were more likely to be sensitized to 1 or none of the
peanut major allergens (61%). Although there was a substantial
overlap between patients with PA and PS patients, there were 2
unique patterns of sensitization: all patients sensitized
simultaneously to Ara h 1 and to Ara h 2 had PA, and all patients
monosensitized to Ara h 1 were PS.
Peanut-specific IgG4 levels were greater in PS
patients compared with those in patients with PA
One hundred one patients (65 patients with PA, 27 PS patients,
and 9 NA subjects) with detectable peanut-specific IgG4
(P-sIgG4) levels were tested for IgG4 to peanut components.
P-IgG4 levels were 1.6-fold higher in PS patients than in patients
with PA (P5.012, see Fig E3 in this article’s Online Repository at
www.jacionline.org). However, there were no significant
differences between the levels of specific IgG4 to peanut
components in patients with PA and PS patients (Table III), except
for Ara h 2–specific IgG4 levels, which were greater in patients
with PA (P 5 .034).
P-sIgG4/P-sIgE ratio was significantly greater in
sensitized but tolerant patients
Overall, the levels and specificity of IgG4 to peanut could not
account for the clinical differences between patients with PA
and PS patients. However, the ratio of specific IgG4 to IgE
directed to peanut was 8 times higher in PS patients compared
with that in patients with PA (Fig 2). The differences
between PS patients and patients with PA were even greater in
the IgG4/IgE ratio to Ara h 1 (18.8-fold, P 5 .05), Ara h 2
(100-fold, P 5 .004), and Ara h 3 (7-fold, P 5 .016). In patients
with PA submitted to POIT (n 5 19), the levels of P-sIgE were
similar before and after treatment, but the levels of P-sIgG4 and
the P-sIgG4/P-sIgE ratio were 12-fold and 10-fold higher after
immunotherapy, respectively (see Table E2 in this article’s
Online Repository at www.jacionline.org). Differences in
P-sIgG4/P-sIgE ratios between patients with PA and PS patients
remained significant after adjusting for specific IgE levels by
using analysis of covariance with ranks (P 5 .001). Similarly,
by using a multivariate logistic regression model, log base
10–transformed IgG4 (P 5 .004) and IgE (P < .001) levels were
both significantly associated with peanut allergy. A relative
importance analysis showed that IgE accounted for 64% of the
model’s explanatory power in predicting patients with PA versus
PS patients, and IgG4 explained the remaining 36%. Patients with
PA tended to have higher levels of IgE to peanut and peanut major
allergens, and PS patients showed a predominance of IgG4 over
IgE (see Fig E4 in this article’s Online Repository at www.
jacionline.org).
Plasma from PS patients was able to inhibit peanut-
induced basophil and mast cell activation similar to
plasma from patients submitted to POIT
Taken together, the previous observations suggested that IgG4
was likely to have an inhibitory role over IgE. We hypothesized
that this would be most relevant to PS patients with IgE directed
to the major peanut allergens Ara h 1, Ara h 2, and Ara h 3. We
tested the ability of plasma from PS patients with IgE directed
to Ara h 1, Ara h 2, and Ara h 3 to inhibit mast cells and basophils
sensitized with plasma from a reference patient with PA also
sensitized to Ara h 1, Ara h 2, and Ara h 3. We used samples of
patients submitted to POIT and of NA subjects as controls.
Peanut-induced mast cell and basophil activation was inhibited
FIG 1. Peanut-induced activation of mast cells (expressed as a percentage
of CD631 LAD2 cells) sensitized with plasma from patients with PA (n 5 6),
PS patients (n 5 5), and NA subjects (n 5 2). Similar results were found for
mast cell activation expressed as a percentage of CD107a1 LAD2 cells.
Values are presented as means and SEs. P values refer to the comparison
between patients with PA and PS patients for each concentration of peanut
extract using the Mann-Whitney U test. **P < .01.
TABLE II. Profiles of IgE sensitization to major peanut aller-
gens in children with PA (n 5 103) and PS children (n 5 76)
Profiles of sensitization
Children with PA,
no. (%)
PS children,
no. (%)
P
value
Ara h 1, 2, and 3 50 (49) 18 (24) .001
Ara h 1 and 2 16 (16) 0 <.001
Ara h 2 and 3 2 (2) 3 (4) .355
Ara h 1 and 3 2 (2) 9 (12) .007
Ara h 1 only 0 12 (16) <.001
Ara h 2 only 28 (27) 16 (21) .234
Ara h 3 only 1 (1) 3 (4) .203
No Ara h 1, 2, or 3 4 (4) 15 (20) .001
The percentage of patients per group is represented. Specific IgE levels of 0.10 KU/L
or greater were considered positive. P values refer to the comparison between patients
with PA and PS patients using the Mann-Whitney U test. Values in boldface indicate
statistical significance.
TABLE III. Serum specific IgG4 levels to peanut and peanut
components in patients with PA and peanut-tolerant patients
(n 5 101)
Specific
IgG4 (mg/L)
Patients with
PA (n 5 65)
Peanut-tolerant subjects
(n 5 36)
P
value*
PS patients
(n 5 27)
NA subjects
(n 5 9)
Peanut 400 (160-960) 650 (430-2140) 160 (100-580) .023
Ara h 1 20 (10-60) 20 (10-80) 10 (0-30) .684
Ara h 2 30 (10-100) 10 (0-40) 10 (0-70) .034
Ara h 3 40 (20-100) 80 (30-190) 30 (20-250) .074
Ara h 8 20 (0-50) 40 (10-100) 10 (0-50) .068
Ara h 9 10 (0-60) 30 (10-1040) 10 (0-20) .065
Values are presented as medians and interquartile ranges.
*P values refer to the comparison between patients with PA and PS patients using the
Mann-Whitney U test. Values in boldface indicate statistical significance.
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in the presence of plasma from PS patients and in the presence of
plasma from patients submitted to POIT but not in the presence
of plasma from NA subjects (Fig 3 and see Figs E5-E8 in this
article’s Online Repository at www.jacionline.org).
Removal of IgG4 antibodies partially restored
peanut-induced mast cell activation
Samples from PS patients with IgE to the 3 major peanut
allergens Ara h 1, Ara h 2, and Ara h 3 and with detectable
P-sIgG4 levels (see Table E3 in this article’s Online Repository at
www.jacionline.org) showed inhibition of peanut-induced mast
cell activation, as did samples from patients submitted to POIT.
To confirm the role of IgG4 in the inhibition of peanut-induced
mast cell activation, we depleted these plasma samples of IgG4
(see Fig E9 and Table E4 in this article’s Online Repository at
www.jacionline.org) and retested IgG4- and mock-depleted
samples in the inhibition of mast cell activation assay. IgG4
depletion from samples from PS patients partially restored
peanut-induced mast cell activation (P 5 .007, Fig 4).
Reduction of mast cell inhibition was also observed when testing
IgG4-depeleted post-POIT samples (P5 .04, see Fig E10 in this
article’s Online Repository at www.jacionline.org).
DISCUSSION
The presence of P-sIgE does not equate to clinical peanut
allergy. The majority of peanut-sensitized patients are peanut
tolerant (ie, able to eat age-appropriate amounts of peanut
without having an allergic reaction). It is possible that different
mechanisms underpin peanut tolerance in different subgroups
of PS patients. In some cases the discrepancy between IgE
levels and clinical reactivity is due to differences in the
specificity of IgE for peanut allergens, such as in PS patients
whose IgE does not recognize any of the major peanut
allergens and binds only to Ara h 8 or Ara h 9. In other cases,
particularly in PS patients with IgE directed to the major
peanut allergens (eg, Ara h 1, Ara h 2, and Ara h 3), which is
known to be able to elicit effector cell activation and
degranulation18,19 and would otherwise be a strong predictor
of peanut allergy, inhibition of IgE by blocking antibodies
might explain in part the absence of allergic symptoms after
peanut ingestion. This study shows that oral tolerance to foods
is associated with the presence of IgG4 in the context of pa-
tients who are producing IgE antibodies. Our results suggest
that this might be due to a direct causal effect of IgG4 or, alter-
natively, to a related effect, such as IL-10; this might also
explain why there are so many more sensitized than allergic
subjects.
Using passive sensitization assays, we reproduced our previous
findings in a whole-blood basophil activation assay5 and
confirmed that the factors responsible for allergen-induced
effector cell activation and unresponsiveness in patients with
PA and PS patients are present in plasma. Other evidence that
supports a role for plasma rather than cellular intrinsic factors
in clinical reactivity to peanut is the fact that clinically determined
FIG 2. IgG4/IgE ratios to peanut and peanut allergens in children with PA
(n 5 65) and PS children (n 5 27). Values are presented as medians and
interquartile ranges. P values refer to the comparison between children
with PA and PS children using the Mann-Whitney U test.
FIG 3. Inhibition of peanut-induced mast cell activation in the presence of
plasma from PS patients with detectable P-sIgG4 levels (n 5 12) and from
patients submitted to POIT (n 5 19) but not in the presence of plasma
from NA subjects (n 5 3). Cells were stimulated with 10 ng/mL peanut
extract. Inhibition was tested against the same plasma of a patient with
PA. % Inhibition 5 (% CD631 cells sensitized with plasma from a patient
with PA 2 % CD631 cells sensitized with plasma from a patient with
PA in the presence of test plasma)/% CD631 cells sensitized with
plasma from a patient with PA. POIT, Patients with PA who underwent
POIT (ie, samples collected >6 months after treatment).
FIG 4. Inhibition of peanut-induced activation of mast cells sensitized with
plasma from a patient with PA in the presence of mock- or IgG4-depleted
plasma samples from peanut-sensitized tolerant patients (median
inhibition, 75% vs 30%, respectively; P 5 .007, n 5 12). % Inhibition 5 (%
CD631 cells sensitized with plasma from a patient with PA2% CD631 cells
sensitized with plasma from a patient with PA in the presence of test
plasma)/% CD631 cells sensitized with plasma from a patient with PA.
The P value refers to the comparison between IgG4- and mock-depleted
paired samples by using the Wilcoxon signed-rank test. **P < .01.
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PS patients who are able to eat peanut without any problems are
often allergic to other foods and airborne allergens. This indicates
that their basophils and mast cells are functional and able to
respond to allergens. Experimentally, basophils from patients
with PA and PS patients have similar IgE receptor expression
on their surface and are able respond to other IgE-mediated
stimulants apart from allergen.20,21 In this study basophil numbers
and baseline activation were similar across groups (see Table E5
in this article’s Online Repository at www.jacionline.org).
Therefore intrinsic differences in cell reactivity between children
with PA and PS children seem an unlikely explanation for the
discrepancy between allergy and sensitization.
At the population level, median serum levels of P-sIgE were
higher in patients with PA comparedwith those in PS patients. This
has been documented in different studies and has formed the basis
of the development of diagnostic cutoffs for P-sIgE levels.22,23
However, at the subject level, there was a great overlap between
patients with PA and PS patients. In a previous study a subgroup
of peanut-sensitized patients with equivocal diagnosis showed no
statistically significant differences in levels of sIgE to peanut com-
ponents between patients with PA and PS patients, except for Ara h
2.5 Patients with PAwere more likely to have IgE directed to Ara h
2 alone or to Ara h 2 in combination with the other peanut major
allergens compared with PS patients and had higher levels on
average. However, some patients with PA did not have detectable
IgE to Ara h 2, and conversely, some PS patients had Ara h 2–
specific IgE levels greater than the cutoffs that have been identified
as being associated with a high probability of clinical peanut al-
lergy.3,24,25 Various examples of patients with PA and PS patients
with the same IgE sensitization pattern to peanut allergens but
with opposite clinical outcomes could be found in our cohort.
Taken together, these observations confirm that the levels and
specificity of P-sIgE do not account for the differences in allergic
reactivity to peanut in all patients with PA and PS patients.
The hypothesis of a peanut-specific antibody counteracting the
ability of P-sIgE to activate and degranulate basophils and mast
cells becomes more plausible in cases in which P-sIgE levels are
high and/or when directed to peanut allergens that are known to be
potent elicitors of effector cell activation, such as Ara h 1, Ara h 2,
and Ara h 3. In these cases IgG4 antibodies and possibly
peanut-specific antibodies of other isotypes block IgE either by
competing with IgE for binding to the peanut allergens or by
inhibiting an activator response at the cellular level by
co–cross-linking of IgE and IgG receptors.26 The 2-step
experimental design used in the mast cell inhibition experiments
allowed not only for a more efficient sensitization phase using
plasma from patients with PA but also to reduce the effect of
IgE in the blocking plasma and the effect of IgG in the sensitizing
plasma. Other factors that could have influenced the results
obtained with the inhibition assay are the possible effects of the
generation of complement-activating (IgG1, IgG2, IgG3, and
IgM) immune complexes and the expression of activating/
inhibitory Fcg receptors and susceptibility to complement
activation products in the effector cells. The use of a
whole-blood basophil activation test assay with removal of
plasma before stimulation with allergen would avoid some of
these issues. Ideally, we would have compared patients with PA
and PS patients with the exact same levels and patterns of
sensitization to different peanut allergens, namely Ara h 2 and
Ara h 8, which have shown in other studies to be the main allergen
in true peanut allergy and the main cause of false-positive peanut
sensitization tests; however, the heterogeneity between patient
groups hindered such a direct comparison.
P-sIgG4 levels were greater in PS patients compared with those
in PA patients, but levels of IgG4 to peanut components were
similar between the 2 groups. Also, in a previous study in children
with egg allergy, specific IgG4 levels to ovomucoid or ovalbumin
were not significantly different between children with baked egg
allergy and tolerant children. Our findings regarding IgG4 were
similar in samples from PS children and samples from patients
submitted to POIT. This is consistent with various POIT
studies,8,27,28 where IgG4 levels have been reported to increase
substantially with treatment and are thought to have a role as a
blocking antibody. In some patients with PA and NA subjects
with detectable P-sIgG4 levels, these antibodies are likely to be
directed to nonallergenic components of peanut or to different
peanut epitopes of peanut allergens compared with IgE and thus
have no ability to block the effect of IgE. In patients with PA,
this results in IgE-mediated effector cell reactivity, whereas in
NA subjects tolerance results from the absence of P-sIgE in the
first instance. Furthermore, in NA subjects there is no inflamma-
tory response against the allergens, and B cells are not affinity
matured; therefore the IgG4 antibodies are of low affinity and
not able to block IgE.
The relative values of IgG4 compared with IgE, rather than
absolute antibody levels, are likely to be the main factor driving
IgE inhibition. The IgG4/IgE ratio to peanut was significantly
greater in PS patients compared with that seen in patients with
PA, indicating that the excess in P-sIgG4 levels in relation to
IgE could block P-sIgE and contribute to the absence of clinical
reactions to peanut in PS patients. In the literature IgE/IgG4 ratios
are usually reported and often not corrected for the fact that IgE
and IgG4 levels are usually measured in different units (IgE in
kilounits per liter and IgG4 in milligrams per liter).
29-31 We
have calculated IgG4/IgE ratios, considering the absolute
amounts of these immunoglobulins in nanograms present in the
serum of each patient at any given moment, which more
accurately reflects the balance between the 2 immunoglobulins
that potentially have opposite effects. The IgG4/IgE ratio to the
peanut major allergens was also higher in PS patients, particularly
to Ara h 2, which is believed to be the most potent elicitor of
effector cell degranulation and, consequently, of allergic
reactions to peanut.19 Our findings are consistent with previous
observations in patients submitted to POIT in whom the increase
in specific IgG4 levels was greatest for Ara h 2–specific IgG4
compared with IgG4 directed to the other peanut allergens
32 or
in whom the increase in Ara h 2–specific IgG4 levels matched
the sensitization profile of existing IgE.33 These observations
support the concepts that Ara h 2 is a dominant allergen in patients
with PA and that IgG4 responses associated with clinical
improvement tend to counteract existing IgE responses. They
also rekindle the discussion on the usefulness of IgG4 assays
and IgG4/IgE ratios for the diagnosis of food allergy; however,
the design of this study does not allow a conclusion on this issue.
Allergen avoidance might influence allergen-specific IgG4 levels
and would need to be taken into consideration. Furthermore, a
well-designed statistical evaluation would be required to establish
the diagnostic usefulness of the differences in component-specific
IgG4 levels between PS patients and patients with PA.
The role of IgG4 in IgE inhibition in samples from PS patients
undergoing POIT was confirmed by depleting this antibody iso-
type from patients’ plasma and observing an overall reduction
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in peanut-induced mast cell inhibition. The fact that the effect of
IgG4 depletion was only partial in some samples suggests that
other antibody isotypes could also have an IgE inhibitory effect.
For example, peanut-specific IgA antibodies could contribute to
the competition with IgE for binding to peanut allergens and
contribute to the overall IgE inhibitory effect; however, in this
population of patients, serum peanut-specific IgA levels were
only detectable in a minority and did not show any differences be-
tween the PA and PS groups (data not shown). Peanut-specific
IgG1 antibodies could also have an inhibitory role; however, we
have not tested for this, which constitutes a limitation of the study.
Other factors that need to be explored to obtain a complete
understanding of the mechanisms bywhich IgE and allergen might
or might not be able to elicit effector cell activation are IgE affinity
and the specific epitopes to which IgE binds.34 It is possible that 2
IgE molecules that are specific for the same peanut allergen recog-
nize different epitopes in the allergen molecule or bind to the same
epitope with different affinities, leading to more or less potent
effector cell activation. Christensen et al,35 using a panel of recom-
binant IgE anti–Der p 2 mAbs with defined specificity, clonality,
and affinity in different combinations, showed very elegantly that
greater specific IgE concentrations, greater specific activity to
Der p 2, and greater epitope diversity increased basophil reactivity,
whereas greater affinity increased basophil sensitivity. Arguably, in
individual peanut-sensitized patients the clinical phenotype is a
result of the combination of different characteristics of the existing
pool of P-sIgE antibodies directed to a certain allergen, aswell as of
the inhibitory activity of IgG4 and possibly other immunoglobulin
isotypes. Additionally, intrinsic differences in the IgG4 molecule
relating to affinity and epitope specificity between patients with
PA and PS patients could further be responsible for inhibiting
mast cell and basophil activation.11
Understanding why some children have low P-sIgE levels and
react when exposed to peanut while others have high P-sIgE
levels but are able to eat peanut without any problems might lead
us to identify future therapeutic targets for children with peanut
allergy. Our data also raise the question of whether the
development of IgG4 mAbs could be used in therapeutic trials.
The known anti-inflammatory properties of IgG4
36 make it a
particularly interesting vehicle for a biological treatment for
peanut and other food allergies in the future.
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Key messages
d At the population level, patients with PA have higher P-
sIgE levels and are more likely to have IgE directed to
Ara h 2 and other peanut major allergens.
d Inhibition of IgE activity by allergen-specific IgG4 and
possibly other antibody isotypes is an alternative mecha-
nism of peanut tolerance in patients with increased spe-
cific IgE levels to peanut and its major peanut allergens.
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